ReviewJournal of clinical medicine2023
Extracorporeal Membrane Oxygenation for Pulmonary Embolism: A Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Outcomes of Venous-Arterial Extracorporeal Membrane Oxygenation Therapy in Acute Pulmonary Embolism: A Single-Center Experience.Journal of thrombosis and thrombolysis · 2026Article
- VenoArterial Extracorporeal Membrane Oxygenation in Cardiac Arrest Suspected due to Massive Pulmonary Embolism: A Case Report.Clinical practice and cases in emergency medicine · 2026Article
- Venoarterial extracorporeal membrane oxygenation as a rescue strategy in high-risk pulmonary thromboembolism.Acute and critical care · 2026Article
- Complications of catheter-directed interventions in acute pulmonary embolism: a narrative expert review with guidance on management.Cardiovascular diagnosis and therapy · 2026Review
- Pulmonary embolism consensus.Archivos de cardiologia de Mexico · 2026Article
- Evolving Management of Acute Pulmonary Embolism with Extracorporeal Membrane Oxygenation-A Narrative Review.Journal of clinical medicine · 2025Review
- Management of High-Risk Pulmonary Thromboembolism Using Conventional Catheter Devices: A Case Report.The American journal of case reports · 2025Article
- Advancements in Pulmonary Embolism Management: Current Approaches and Future Directions.Reviews in cardiovascular medicine · 2025Review
- The latest in the management of pulmonary embolism.Breathe (Sheffield, England) · 2025Review
- Management of high-risk acute pulmonary embolism: an emulated target trial analysis.Intensive care medicine · 2025Observational
- Mechanical Circulatory Support for Massive Pulmonary Embolism.Journal of the American Heart Association · 2025Review
- Real-world clinical outcomes of EKOS catheter-directed thrombolysis versus systemic alteplase in acute pulmonary embolism: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- The Five Pillars of Acute Right Ventricular Heart Failure Therapy: Can We Keep the Pediment in Balance?Journal of clinical medicine · 2024Article
- Mortality rate and factors associated with in-hospital mortality in patients hospitalized with pulmonary embolism in Germany.Journal of thrombosis and thrombolysis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of extracorporeal membrane oxygenation (ECMO) for high-risk pulmonary embolism (HRPE) with haemodynamic instability or profound cardiogenic shock has been reported. Guidelines currently support the use of ECMO only in patients with cardiac arrest or circulatory collapse and in conjunction with other curative therapies. We aimed to characterise the mortality of adults with HRPE treated with ECMO, identify factors associated with mortality, and compare different adjunct curative therapies.
methodsWe conducted a systematic review and meta-analysis, searching four international databases from their inception until 25 June 2023 for studies reporting on more than five patients receiving ECMO for HRPE. Random-effects meta-analyses were conducted. The primary outcome was in-hospital mortality. A subgroup analysis investigating the outcomes with curative treatment for HRPE was also performed. The intra-study risk of bias and the certainty of evidence were also assessed. This study was registered with PROSPERO (CRD42022297518).
resultsA total of 39 observational studies involving 6409 patients receiving ECMO for HRPE were included in the meta-analysis. The pooled mortality was 42.8% (95% confidence interval [CI]: 37.2% to 48.7%, moderate certainty). Patients treated with ECMO and catheter-directed therapy (28.6%) had significantly lower mortality (
conclusionsMore than 50% of patients receiving ECMO for HRPE survive. While outcomes may vary based on the curative therapy used, early ECMO should be considered as a stabilising measure when treating patients with HRPE. Patients treated concurrently with systemic thrombolysis have higher mortality than those receiving ECMO alone or with other curative therapies, particularly catheter-directed therapies. Further studies are required to explore ECMO vs. non-ECMO therapies in view of currently heterogenous datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.